The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405.
 
Michela Bartolini
No Relationships to Disclose
 
Francesca Battaglin
No Relationships to Disclose
 
Joshua Millstein
No Relationships to Disclose
 
Fang-Shu Ou
No Relationships to Disclose
 
Shivani Soni
No Relationships to Disclose
 
Pooja Mittal
No Relationships to Disclose
 
Sandra Algaze
Consulting or Advisory Role - Elevar Therapeutics
 
Karam Ashouri
No Relationships to Disclose
 
Lesly Torres-Gonzalez
No Relationships to Disclose
 
Unnati Shah
No Relationships to Disclose
 
Priya Jayachandran
No Relationships to Disclose
 
Wu Zhang
No Relationships to Disclose
 
Alan Venook
Consulting or Advisory Role - Abbvie; Amgen; Eisai; Exact Sciences; Exelixis; INTERA; Pfizer
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Federico Innocenti
Employment - Abbvie; BeiGene
Stock and Other Ownership Interests - AbbVie; BeiGene
Patents, Royalties, Other Intellectual Property - United States Patent: "Flavopiridol drug combinations and methods with reduced side effects", Ratain MJ, Innocenti F, Iyer L. Filed on April 12, 2001, serial number 09/835,082.; United States Patent: “Methods of identifying risk of bevacizumab-induced proteinuria and hypertension”, Innocenti F, Quintanilha J, Lin D, Owzar K, Wang J. Filed on July 17, 2020, serial number 16/932,002.; United States Patent: “Optimization of cancer treatment with irinotecan”, Ratain MJ, Innocenti F, Karabatsos P, Grimsley C, Di Rienzo A. Filed on February 12, 2003, serial number 60/446,942.
 
Alberto Puccini
Consulting or Advisory Role - Bayer; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; MSD; Takeda
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Serono
 
Heinz-Josef Lenz
Honoraria - Abbvie; Adagene; Bayer; Boehringer Ingelheim; Fulgent Genetics; Janssen Oncology; Jazz Pharmaceuticals; Merck Serono; Merus; Roche
Consulting or Advisory Role - 3T BioSciences; Abbvie; Adagene; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono